Yesterday, Regeneron Pharmaceuticals (NASDAQ: REGN) announced that EYLEA® (aflibercept) Injection was approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

The approval was for EYLEA treatment initiated with one 2 milligram (mg) injection per month for three consecutive months, followed by one injection every two months. There is no requirement for monitoring by the physician between injections. After the first twelve months of treatment with EYLEA, the treatment interval may be extended based on visual and anatomic outcomes. In such cases, the frequency of monitoring visits is determined by the treating physician and may be more often than the schedule of injections.

EYLEA was approved for the treatment of neovascular (wet) AMD in the United States in November 2011.

Click here ^[1] to read the complete release.